Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1647 CMV Vaccine in Allogeneic HCT Patients
NCT05683457Phase 2Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Apr 2023
- Primary completion
- Mar 2027
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of mRNA-1647 in cytomegalovirus infection (CMV), sponsored by Moderna Inc. Started Apr 2023; status: active, not recruiting.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05683457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683457.